This is the third U.S. patent awarded to GBS's disease-specific Cannabinoid-Containing Complex Mixtures (CCCM™), which further validates GB Sciences' drug discovery platform and strengthens its intellectual property patent portfolio
Read MoreThis marks GB Sciences' second US Patent approval for a cannabis-based complex mixture, further solidifying both GB Sciences' Drug Discovery platform and its intellectual property patent portfolio.
Read MoreThis is the first time a Cannabinoid-Containing Complex Mixture (CCCM™) has been awarded a U.S. patent, which thereby validates GB Sciences' drug discovery platform and strengthens its intellectual property patent portfolio
Read More